Natco Pharma Ltd.

Natco Pharma has received an approval for generic Sofosbuvir tablets, 400mg, from Drugs Controller General (India). Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi.

The pharma major will market generic Sofosbuvir under its brand HEPCINAT and through strategic partners in India. It plans to price its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets and expects to launch in India very soon.

Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.